Desvenlafaxine extended release

CNS Drugs

Volumn 22, Issue 12, 2008, Pages 1061-1069

  Yang, Lily P H ^a,b   Plosker, Greg L ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug profiles; Antidepressants, therapeutic use; Depression; Depressive disorders; Desvenlafaxine, adverse reactions; Desvenlafaxine, pharmacodynamics; Desvenlafaxine, pharmacokinetics; Desvenlafaxine, therapeutic use

Indexed keywords

DESVENLAFAXINE; DULOXETINE; MIDAZOLAM; PRISTIQ; UNCLASSIFIED DRUG;

AGITATION; ANORGASMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EXTENDED RELEASE FORMULATION; FATIGUE; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; ORGASM; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; SUSTAINED HYPERTENSION; VOMITING; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS;

EID: 55949091761     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/0023210-200822120-00008     Document Type: Review

References (29)

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008 Jan 3; 358 (1): 55-68
2. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. The ESEMeD/MHEDEA 2000 Investigators. Acta Psychiatr Scand Suppl 2004 Jun; 109 Suppl. 420: 21-7
3. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005 Oct; 62 (10): 1097-106
4. Üstün TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004 May; 184: 386-92
5. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder: second edition [online]. Available from URL: http://www.psychiatry-online.com/pracGuide/loadGuidelinePdf.aspx?file= MDD2-e_05-15-06 [Accessed 2008 Jul 3]
6. National Institute for Health and Clinical Excellence. NICE clinical guideline 23 (amended): management of depression in primary and secondary care [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ CG23NICEguidelineamended.pdf [Accessed 2008 Jul 3]
7. Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001; 15 (8): 643-69
8. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 2007; 21 (7): 581-609
9. Wyeth Pharmaceuticals Inc. FDA approves Pristiq for the treatment of adult patients with major depressive disorder [online]. Available from URL: http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/ pressreleases/2008/ 1204331198948.html [Accessed 2008 Jul 29]
10. Wyeth Pharmaceuticals Inc. Pristiq (desvenlafaxine) extended-release oral tablets: US prescribing information [online]. Available from URL: http://www.wyeth.com/content/showla50beling.asp?id=497 [Accessed 2008 Jul 1]
11. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006 Aug; 318 (2): 657-65
12. Paul J, Behrle JA, Richards LS, et al. Double-blind, placebo-and moxifloxacin-controlled crossover study of the effects of desvenlafaxine succinate on QT interval in healthy adult female subjects [abstract no. NR571 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON), 238
13. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 2007; 68 Suppl. 8: 26-34
14. Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. Epub 2008 Sep 22
15. Patat A, Baird-Bellaire S, Behrle J, et al. Lack of clinically relevant effect of pharmacokinetic interaction between ketoconazole on and desvenlafaxine-SR pharmacokinetics [abstract no. PII-50]. Clin Pharmacol Ther 2007 Mar; 81 Suppl. 1: S64
16. Preskorn S, Patroneva A, Nichols A, et al. A comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine succinate in healthy subjects [abstract no. P.2.b.013]. Eur Neuropsychopharmacol 2007 Oct; 17 Suppl. 4: S339
17. Parker VD, Richards LS, Nichols AI, et al. The absolute bioavailability of an oral sustained-release formulation of desvenlafaxine succinate in healthy subjects [abstract no. PI-149]. Clin Pharmacol Ther 2005 Feb; 77 (2): P47. Plus poster presented at the 2005 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2005 Mar 2-6; Orlando (FL)
18. Shilling AD, Oganesia A, Young-Sciame R, et al. Desvenlafaxine succinate, venlafaxine, duloxetine, paroxetine, sertraline, and bupropion: comparing inhibitory effects on human cytochrome P450 and P-glycoprotein activities [abstract no. P02.050]. Int J Neuropsychopharmacol 2006 Jul; 9 Suppl. 1: S177. Plus poster presented at the 25th Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2006 Jul 9-13; Chicago (IL)
19. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008 Jul; 24 (7): 1877-90
20. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008 Sep; 23 (5): 243-53
21. Wyeth Pharmaceuticals Inc. Final report: a multicenter, randomized, double-blind, placebo-controlled, duloxetine-referenced, parallel-group study to evaluate the efficacy and safety of 2 fixed doses (50 mg, 100 mg) of desvenlafaxine sustained release tablets in adult outpatients with major depressive disorder; synopsis based on final report (protocol 3151A1-335) [online]. Available from URL: http://www.clinicalstudyresults.org/documents/ company-study_3949_0.pdf [Accessed 2008 Jul 23]
22. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007 Nov; 68 (11): 1663-72
23. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007 May; 68 (5): 677-88
24. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007 Nov; 22 (6): 338-47
25. Ahmed S, Patroneva A, Graepel J, et al. Improvement of anxiety symptoms in patients with major depressive disorder treated with desvenlafaxine: a pooled analysis [abstract no. NR3-145 plus poster]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC, 156
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatrtic Association, 1994
27. Clayton A, Kornstein SG, Rosas G, et al. Pooled analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder [abstract no. NR5-083 plus poster]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC, 250-1
28. Montgomery SA, Fava M, Tourian KA, et al. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder [abstract no. NR5-038 plus poster]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC, 229-30
29. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998 Jul 15; 44 (2): 77-87